Tempus Growth, Revenue, Number of Employees and Funding

Overview

Location:
Chicago, IL USA
Total Funding:$260M
Industry:Biotech
Founded:2015
Lead Investor(s):Baillie Gifford
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

    0
  • Tempus received $110.0M in venture funding in August 2018.
  • 0
  • Tempus's total funding is $260M.

Employee Data

  • Tempus has 656 Employees.
  • Tempus grew their employee count by 62% last year.
  • Tempus currently has 55 job openings.

Executive Contacts

NameTitle
Amy Gordon FranzenSenior Director Of Operations
Britt OergelVice President, East Coast
Laura ElsterVice President, US Sales
Jennifer ClausonClinical Research Operations Director
Matt LoveVice President, Business Development
Robert TellSr Director, Bioinformatics
Jeff SchaefferSenior Director, Product Management
Jim RogersSenior Director of Finance
Ryan FukushimaChief Operating Officer
Eric SingleyVice President of Product

What Is Tempus?

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and visit us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.

keywords:N/A

656

Number of Employees

N/A

Revenue (est)

55

Current Jobs

62%

Employee Growth %

$260M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Aptinyx
$6.7M56-12%$237.4M
Heidolph North ...
$5.7M5116%
Exicure
N/A3716%
Project Farma
$15M6824%
Tempus
N/A65662%$260M
AveXis
$145.5M111202297%$170.5M

Tempus News

12-Sep-19 - Genmab and Tempus Enter into Strategic Collaboration ...

Genmab and Tempus sign agreement to research and develop ... that it has entered into a strategic collaboration agreement with Tempus, ...

07-Sep-19 - Tempus Expands Its Management Team With the Appointment ...

CHICAGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the collection and ...

12-Sep-19 - Precision medicine startup Tempus snags Mount Sinai, FDA ...

Tempus, a Chicago-based biotech startup building a massive library of clinical and molecular data and an accompanying machine ...

Tempus Funding

DateAmountRoundLead InvestorsReference
2017-09-26$70.0MCNew Enterprise AssociatesArticle
2018-03-21$80.0MUndisclosedT. Rowe PriceArticle
2018-08-30$110.0MEBaillie GiffordArticle

Tempus Executive Hires

DateNameTitleReference
2017-04-06Erik PhelpsVP General CounselArticle